Therefore, in the guidelines and consensus on diabetes prevention and treatment of various countries, SGLT-2 inhibitors are recommended for the treatment of T2DM patients with established cardiovascular disease or high risk of cardiovascular disease. Here, SLC5A2 is linked to type 2 diabetes mellitus.